See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Yijun Hua
Sun Yat-sen University Cancer Center
Corresponding Author
ORCiD: https://orcid.org/0000-0003-0998-8695
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Backgrounds: To assess the efficacy of Nimotuzumab in combination with first-line treatment of chemoradiotherapy of Chinese patients with primary III-IVb stage nasopharyngeal carcinoma. Methods: Patients with primary locoregionally advanced nasopharyngeal carcinoma who were treated with intensity-modulated radiotherapy (IMRT) and concurrent Cisplatin-based chemotherapy between January, 2008 and December, 2013 at a single institution were retrospectively reviewed. Group A received at least 6 doses of Nimotuzumab; Group B did not received Nimotuzumab. A propensity score matching method was used to match patients from each group in a 1:3 ratio. Results: In total, 730 eligible patients were propensity-matched, with 184 patients in Group A and 546 in Group B. There were no significant differences in patient and tumor characteristics between Group A and Group B. At a median follow-up of 74.78 months (range 3.53–117.83 months), locoregional recurrence, distant failure and death were observed in 10.68%, 11.10% and 16.03% of all patients, respectively. Estimated 5-year locoregional relapse–free survival, distant metastasis–free survival, progression-free survival and overall survival in the Group A versus Group B were: 85.34% versus 89.79% (P=0.156), 93.09% versus 85.61% (P = 0.012), 79.96% versus 77.99% (P = 0.117) and 88.91% versus 78.30% (P=0.006), respectively. Conclusions: This nimotuzumab-containing regimen resulted in a better long-term survival in III-IVb stage NPC patients, and warrants further prospective evaluation.
Keywords
Nasopharyngeal Carcinoma, IMRT, Chemotherapy, Nimotuzumab, Prognosis
Figure 1
Figure 2
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 18 Nov, 2019
Editorial decision: Accept
On 13 Sep, 2019
Editor assigned
On 10 Sep, 2019
Editor invited
On 09 Sep, 2019
No comments provided
Editorial decision: Minor revision
On 27 Aug, 2019
Version 1
Posted 28 Aug, 2019
No comments provided
Editorial decision: Minor revision
On 29 Jul, 2019
Review #2 received
Received 28 Jul, 2019
Review #1 received
Received 26 Jul, 2019
Reviewer #1 agreed
On 11 Jul, 2019
Reviewer #2 agreed
On 11 Jul, 2019
Editor assigned
On 08 Jul, 2019
Reviewers invited
Invitations sent on 08 Jul, 2019
Submission checks complete
On 28 Jun, 2019
Editor invited
On 24 Jun, 2019
First submitted
On 10 Jun, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Yijun Hua
Sun Yat-sen University Cancer Center
Corresponding Author
ORCiD: https://orcid.org/0000-0003-0998-8695
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 18 Nov, 2019
Editorial decision: Accept
On 13 Sep, 2019
Editor assigned
On 10 Sep, 2019
Editor invited
On 09 Sep, 2019
No comments provided
Editorial decision: Minor revision
On 27 Aug, 2019
Version 1
Posted 28 Aug, 2019
No comments provided
Editorial decision: Minor revision
On 29 Jul, 2019
Review #2 received
Received 28 Jul, 2019
Review #1 received
Received 26 Jul, 2019
Reviewer #1 agreed
On 11 Jul, 2019
Reviewer #2 agreed
On 11 Jul, 2019
Editor assigned
On 08 Jul, 2019
Reviewers invited
Invitations sent on 08 Jul, 2019
Submission checks complete
On 28 Jun, 2019
Editor invited
On 24 Jun, 2019
First submitted
On 10 Jun, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Backgrounds: To assess the efficacy of Nimotuzumab in combination with first-line treatment of chemoradiotherapy of Chinese patients with primary III-IVb stage nasopharyngeal carcinoma. Methods: Patients with primary locoregionally advanced nasopharyngeal carcinoma who were treated with intensity-modulated radiotherapy (IMRT) and concurrent Cisplatin-based chemotherapy between January, 2008 and December, 2013 at a single institution were retrospectively reviewed. Group A received at least 6 doses of Nimotuzumab; Group B did not received Nimotuzumab. A propensity score matching method was used to match patients from each group in a 1:3 ratio. Results: In total, 730 eligible patients were propensity-matched, with 184 patients in Group A and 546 in Group B. There were no significant differences in patient and tumor characteristics between Group A and Group B. At a median follow-up of 74.78 months (range 3.53–117.83 months), locoregional recurrence, distant failure and death were observed in 10.68%, 11.10% and 16.03% of all patients, respectively. Estimated 5-year locoregional relapse–free survival, distant metastasis–free survival, progression-free survival and overall survival in the Group A versus Group B were: 85.34% versus 89.79% (P=0.156), 93.09% versus 85.61% (P = 0.012), 79.96% versus 77.99% (P = 0.117) and 88.91% versus 78.30% (P=0.006), respectively. Conclusions: This nimotuzumab-containing regimen resulted in a better long-term survival in III-IVb stage NPC patients, and warrants further prospective evaluation.
Figure 1
Figure 2
Loading...